ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

Panel To Take Up Issues In Grant/Peer Review System, Consider NCAB Membership Requirements

December 11, 1981

In Brief: Treatment Reorganization Will Give Rauscher “Lumps,” He Says; Coordinating Group Favored

August 16, 1974

In Brief: Henney Permanent NCI Deputy Director; 17 Regional Cooperative Group Applications Get First Review

February 5, 1982

Cancer Letter, PR Firm Settle Out Of Court On Copyright Violation

November 27, 1987

NCAB Approves Year 2000 Report; Implementation Depends On Adequate Funding Starting With FY 1986

July 12, 1985

ONS The Largest And Still Growing With 13,000 Members

May 27, 1988